Tag: GLP-1
Browse all articles tagged with “GLP-1”.
11 articles
Semaglutide and the GLP-1 Revolution: What Researchers Need to Know
A comprehensive research overview of semaglutide, the GLP-1 receptor agonist that has reshaped metabolic health research with over 169 PubMed studies, $29.3B in revenue, and expanding clinical applications from weight management to cardiovascular outcomes.
Semaglutide vs Tirzepatide: GLP-1 Agonist Comparison
A comprehensive comparison of semaglutide and tirzepatide, the two leading GLP-1 receptor agonists. Examine clinical trial data, mechanisms, efficacy, side effects, cost, and FDA approval status.
Tirzepatide: The Dual GIP/GLP-1 Receptor Agonist Reshaping Metabolic Research
A comprehensive research overview of tirzepatide, the dual GIP/GLP-1 receptor agonist marketed as Mounjaro and Zepbound. Explore its mechanism, SURMOUNT and SURPASS trial data, $16.5B revenue trajectory, and how it compares to semaglutide.
Peptide Clinical Trials Are Surging: What It Means for Research in 2026
An in-depth look at the explosion of peptide clinical trials in 2026, driven by GLP-1 success, AI-accelerated discovery, and expanding therapeutic applications across cancer, neurodegeneration, and metabolic disease.
Retatrutide: The Triple Agonist Setting New Records in Obesity Research
A research-focused overview of retatrutide (LY3437943), the investigational triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly that achieved 23.7% body weight reduction in Phase 2 trials, the largest ever recorded in an obesity trial.
The Complete Guide to GLP-1 Receptor Agonists: From Semaglutide to Retatrutide
An in-depth comparison of every major GLP-1 receptor agonist in research and clinical development, including semaglutide, tirzepatide, retatrutide, liraglutide, cagrilintide, survodutide, and mazdutide. Mechanism differences, efficacy data, and market positions.
What Is Semaglutide? A Research Overview
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most studied compounds for weight management and metabolic health.
What Is Tirzepatide? A Research Overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist that represents a new class of incretin-based therapeutics for type 2 diabetes and obesity management.
Liraglutide: The First-Generation Daily GLP-1 That Paved the Way
A comprehensive overview of liraglutide (Saxenda/Victoza), the first-generation daily GLP-1 receptor agonist with 97% homology to human GLP-1 that established the foundation for the entire class of incretin-based metabolic therapies.
Survodutide: The Dual Glucagon/GLP-1 Agonist Targeting Liver Disease
A research overview of survodutide, the investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim being developed for obesity and NASH/MASH, with a focus on its hepatic fat reduction potential.
Mazdutide: The Dual GLP-1/Glucagon Agonist From Innovent Biologics
A research overview of mazdutide (IBI362), the dual GLP-1/glucagon receptor agonist developed by Innovent Biologics for the Chinese and global markets, with Phase 3 data showing significant weight loss and metabolic improvements.
For informational purposes only. Not medical advice. Always consult with qualified healthcare professionals.